Yahoo cowboys!! BIOI has gone from dead last on John Bollingers Equitytrader.com's fuzzy logic model to first - in the space of 3 1/2 months see: equitytrader.com - an awesome "two green lights" - a strong buy.
Obviously his fuzzy logic uses momentum as one of the variables, probably heavily weighted, for short term trading purposes, so I generally ignore this type of stuff. But with my stash of this company I'm pleased we are where we are at.
Also had a great interview with Jim McCamant of the Medical Technology Letter late last week - he follows biotech - and he is astounded at how cheap many of the biotech drug development companies are, as well as small caps. He sees a recovery, for a number or reasons, both in biotech and in small caps. I agree with his assessment, but prefer to buy companies making money in this sector at reasonable prices, which is where BIOI has fit in.
McCamant will be up at audioinvestor.com on Thursday or Friday for biotech fans that want to get a fill of what he thinks. He is a very interesting guy, and sure has an opinion that he is not afraid to give (especially regarding Amgen).
I should have asked him about BIOI to see if he had run across it, but did not since we are so small and have such a limited following here that I thought the question would not be of interest to most.
I've asked BIOI if they would post a delayed replay of their conference calls (earnings) at the AudioInvestor.Com site but have gotten no response. Would be nice to have access, since most of us do not have the time to break away from work and listen. The Dallas Morning News is going to use AudioInvestor.Com interviews and materials which would give BIOI much greater exposure to a lot of people in the Southwest, anyway.
Joe |
